Microbot Medical (MBOT) vs Sera Prognostics (SERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sera Prognostics (SERA) has outperformed Microbot Medical (MBOT) over the past year, losing 35.9% versus a loss of 67.5%. Over five years, SERA leads with a -81.4% price change compared with -85.1% for MBOT. Sera Prognostics is the larger company by market cap ($82.8 million vs $72.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBOT | SERA |
|---|---|---|
| Share price | $1.08 | $2.10 |
| Market cap | $72.20M | $82.80M |
| 1-day change | +0.47% | +3.91% |
| YTD return | -46.50% | -31.53% |
| 1-year return | -67.48% | -35.87% |
| 5-year return | -85.08% | -81.38% |
| EPS (TTM) | $-0.25 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.17 | $3.95 |
| 52-week low | $1.05 | $1.56 |
| Distance from 52-week high | -66.09% | -46.86% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +488.84% | +162.03% |
| Average volume | 649.10K | 27.84K |
| Shares outstanding | 67.16M | 38.48M |
| Employees | 43 | 71 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SERA has outperformed MBOT by 31.6 percentage points over the past year.
About Microbot Medical
MBOT stock →Microbot Medical Inc. is a medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space.
Health Care · Medical/Dental Instruments · 43 employees
About Sera Prognostics
SERA stock →Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Health Care · Medical Specialities · 71 employees
MBOT vs SERA FAQ
Which is bigger, Microbot Medical or Sera Prognostics?
Sera Prognostics (SERA) is larger, with a market capitalization of $82.80M compared with $72.20M for Microbot Medical (MBOT).
Which stock has performed better over the past year, MBOT or SERA?
SERA returned -35.87% over the past 12 months, compared with -67.48% for MBOT (price return, excluding dividends). Past performance does not predict future results.
Are Microbot Medical and Sera Prognostics in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Microbot Medical and Medical Specialities for Sera Prognostics.